RU97113692A - APPLICATION OF 3,4-DIPHENYLCHROMANES FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CEREBRAL DEGENERATIVE DISORDERS - Google Patents

Claims (19)

1. The use of compounds of General formula I

in which R ¹ , R ⁴ and R ⁵ individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R ² and R ³ are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for preparing a pharmaceutical composition for treating or preventing cerebral degenerative disorders, for example, Alzheimer's disease. 2. The use according to claim 1, in which the specified connection has the General formula III:

where R ¹ , R ² , R ³ , R ⁴ and R ⁵ each has the meaning given in claim 1. 3. The use according to claim 1 or 2, in which R ¹ is lower alkoxy, preferably methoxy. 4. Use according to any one of the preceding claims, wherein R ² is lower alkyl, preferably methyl. 5. The use according to any one of the preceding paragraphs, in which R ³ represents lower alkyl, preferably methyl. 6. The use according to any one of the preceding paragraphs, in which R ⁴ represents hydrogen. 7. The use according to any one of the preceding paragraphs, in which R ⁵ is a (tertiary amino) (lower alkoxy), preferably 2- (pyrrolidin-1 -yl) ethoxy.  8. The use according to any one of the preceding claims, wherein said compound is a stereoisomer, for example, an isolated d or l-enantiomer.  9. The use according to any one of the preceding claims, wherein said compound is an isolated l-enantiomer.  10. The use according to claim 1, wherein said compound is 3,4-trans-2.2-dimethyl-3-phenyl-4- [4- (2- (pyrrolidin-1-yl) ethoxy) phenyl)] -7 -metoksikhroman.  11. The use according to the preceding paragraph, wherein said compound is an isolated d- or l-enantiomer of 3,4-trans-2.2-dimethyl-3-phenyl-4- [4- (2- (pyrrolidin-1-yl) ethoxy ) phenyl)] - 7-methoxychroman.  12. The use according to claim 11, wherein said compound is 1-3,4-trans-2.2-dimethyl-3-phenyl-4- [4- (2- (pyrrolidin-1-yl) ethoxy) phenyl)] -7-methoxychroman.  13. The use according to any one of the preceding claims, wherein said composition is in a form suitable for oral administration.  14. The use according to any one of the preceding paragraphs, wherein said compound is administered as a dose in the range from approximately 0.001 to 75, preferably in the range from approximately 0.01 to 75, more preferably in the range from approximately 0.01 to 50 , and especially, in the range from approximately 0.1 to 25 mg / kg of patient weight per day.  15. The use according to any one of the preceding claims, wherein said composition is applied one or more times a day or a week.  16. The use according to any one of the preceding claims, wherein said composition is in the form of a dermal implant.  17. A method of treating and preventing cerebral degenerative disorders, for example Alzheimer's disease, comprising administering to the patient a therapeutically effective amount of compounds of formula I, as claimed for use in any of the preceding points of use, or a pharmaceutically acceptable salt thereof in an amount sufficient to treat or prevent cerebral degenerative disorders such as Alzheimer's disease.  18. A method for treating or preventing cerebral degenerative disorders, such as Alzheimer's disease, the method comprising administering a therapeutically effective amount of a compound of formula I or a salt thereof and pharmaceutically acceptable compositions containing such a compound to a patient in need of such treatment.  19. Any new feature or combination of features described here.